Robert Armstrong There has been a wild and hectic series of M&A deals in the pharmaceuticals industry. We are now headed for ...
Rising costs and complex care make diabetes a daily challenge. Local patient and pharmacy expert share strategies, struggles, ...
As costs for seniors continue to climb, U.S. Sen. Kirsten Gillibrand of New York, the top Democrat on the Senate Special Committee on Aging, demanded Tuesday that President Trump release the list of ...
Stockhead on MSN
The art of the health deal: How strong data opens doors
Strong clinical data doesn’t just move share prices – it can unlock lucrative global licensing deals for ASX-listed ...
Senator Gillibrand’s call comes as the cost of groceries, energy, and other everyday essentials continue to climb for American seniors, while Social Security cost-of-living adjustments fail to keep ...
Federal annuitants often don't have the same flexibility as federal employees when it comes to offsetting their health ...
SGLT2 inhibitors are a welcome addition to GN care, but the field is still grappling with the gap between molecular ...
RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal ...
MOAT employs a value strategy, targeting companies with strong competitive advantages trading at discounts. Read why I rate ...
Johnson & Johnson has agreed to acquire Halda Therapeutics for $3.05 billion cash, in a deal designed to expand the buyer’s cancer pipeline with Halda’s precision oncology candidates, led by a ...
Young and the Invested on MSN
Our 9 favorite dividend funds for 2026
Dividend stocks are one of the primary building blocks of a portfolio, providing investors not just with the growth potential ...
Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback